Celltrion Healthcare, 1,415,180 Shares Net Bought by Individuals Over Last 5 Days... Stock Price at 153,600 Won (+7.11%)

As of 12:30 PM on the 18th, Celltrion Healthcare is trading at 153,600 KRW, up 7.11% from the previous day. The trading volume is 3,158,406 shares, which is 55.03% of the previous day's volume. Celltrion Healthcare is known as the exclusive distributor of Celltrion's biosimilars.

On January 18, researcher Han Byunghwa of Eugene Investment & Securities stated, "The stock price sharply dropped in the short term due to mixed views on the clinical results of Rekkeona Injection. We believe the published clinical data is sufficient for emergency approval both domestically and internationally. Additionally, we consider that the COVID-19 antibody treatment plays an appropriate role in filling the gap left by vaccines. Pandemics caused by worsening climate crises are inevitable to recur periodically in the future. The know-how Celltrion Group has secured this time regarding the development, manufacturing, and sales of Rekkeona Injection will be a key driver for being recognized as a global big pharma." He set the target price of Celltrion Healthcare at 190,000 KRW.

Over the past five days, individual investors have net purchased 1,415,180 shares of Celltrion Healthcare, while foreigners and institutions have net sold 1,002,437 shares and 423,966 shares, respectively.

※ Source: AI Investment Assistant AI Rassiro

※ This article was generated in real-time by an automatic article generation algorithm jointly developed by Asia Economy and the financial AI specialist company Thinkpool.